Wedbush Securities’s Clovis Oncology, Inc. CLVS Stock Holding History

Wedbush Securities’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,200	Closed	-$1K	–	1151
2022 Q4	$1K	Hold	20,200	–	–	﹤0.01%	1057
2022 Q3	$24K	Hold	20,200	–	–	﹤0.01%	1029
2022 Q2	$36K	Buy	20,200 +500	+3%	+$738	﹤0.01%	1046
2022 Q1	$40K	Sell	19,700 -150	-0.8%	-$295	﹤0.01%	1084
2021 Q4	$54K	Sell	19,850 -5,500	-22%	-$20.3K	﹤0.01%	1154
2021 Q3	$113K	Buy	25,350 +1,800	+8%	+$8.67K	0.01%	1125
2021 Q2	$137K	Buy	23,550 +3,900	+20%	+$22.9K	0.01%	1107
2021 Q1	$138K	Buy	19,650 +1,900	+11%	+$12.7K	0.01%	1029
2020 Q4	$85K	Buy	17,750 +1,800	+11%	+$9.1K	0.01%	842
2020 Q3	$93K	Buy	15,950 +3,000	+23%	+$17.9K	0.01%	835
2020 Q2	$87K	Buy	+12,950	New	+$98.1K	0.01%	868

Other funds holding CLVS

RMC

Resources Management Corp West Hartford, Connecticut $794M AUM 25.46% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Wedbush Securities's CLVS Position: Q1 2023 in Review

Wedbush Securities sold out of Clovis Oncology, Inc. (CLVS) in Q1 2023, closing a stake of 20,200 shares — an estimated $1K sold.

Wedbush Securities first reported a position in CLVS in Q2 2020 and held it in 11 quarters. The position peaked at $138K in Q1 2021. 2 funds tracked by Wall St. Rank hold CLVS as of Q1 2023.

Wedbush Securities reported no remaining Clovis Oncology, Inc. position as of Q1 2023 after selling out during the quarter.
Wedbush Securities sold 20,200 Clovis Oncology, Inc. shares in Q1 2023, an estimated $1K.
Wedbush Securities first reported a position in Clovis Oncology, Inc. in Q2 2020 and held it in 11 quarters.
Wedbush Securities's Clovis Oncology, Inc. position peaked at $138K in Q1 2021.
2 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2023.

Based on Wedbush Securities's 13F filing for Q1 2023, filed 9 May 2023.